Loading...
•
Jun 30, 2024
Bruker Q2 2024 Earnings Report
Bruker's Q2 2024 financial results were released, showing revenue growth and strategic acquisitions.
Key Takeaways
Bruker reported strong Q2 2024 results with revenues of $800.7 million, up 17.4% year-over-year, and organic revenue growth of 7.4%. The company's non-GAAP EPS increased by 4.0% to $0.52. Bruker has increased its full-year revenue guidance to $3.38-$3.44 billion, which now includes the NanoString business.
Q2 2024 revenues reached $800.7 million, a 17.4% increase year-over-year.
Organic revenue grew by 7.4% year-over-year.
GAAP EPS was $0.05, while non-GAAP EPS was $0.52, up 4.0% year-over-year.
Full-year 2024 revenue guidance increased to $3.38-$3.44 billion, including the NanoString business.
Bruker
Bruker
Bruker Revenue by Segment
Bruker Revenue by Geographic Location
Revenue by Segment
Bruker BioSpin Revenue
CapyFin.comBruker CALID Revenue
CapyFin.comBruker Nano Revenue
CapyFin.comBEST Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comEurope Revenue
CapyFin.comAsia Pacific Revenue
CapyFin.comOther Revenue
CapyFin.com Forward Guidance
Bruker now expects FY 2024 revenues of $3.38 to $3.44 billion, with 14% to 16% year-over-year reported revenue growth. Bruker now expects FY 2024 non-GAAP EPS of $2.59 to $2.64.
Positive Outlook
- Organic revenue growth of 5% to 7%.
- M&A tailwind of approximately 10%.
- CER revenue growth of 15% to 17%.
- Revenue between $3.38 to $3.44 billion
- Non-GAAP EPS of $2.59 to $2.64
Challenges Ahead
- A foreign currency translation revenue headwind of approximately -1%.
- Impact of supply chain challenges, including inflationary pressures
- Impact of geopolitical tensions and any sanctions
- Conflict in Israel, Palestine and surrounding areas
- Ongoing tensions between the United States and China
Revenue & Expenses
Visualization of income flow from segment revenue to net income